NRNayebali Rezvani

Nayebali Rezvani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nayebali Rezvani has a total of 45 co-authors. Here are the top co-authors by number of shared publications:

  • Bayan Mehrjoei

    Department of Clinical Biochemistry, Kermanshah University of Medical Sciences, Kermanshah, Iran

    3 shared publications
  • Lida Haghnazari

    Department of Clinical Biochemistry, Kermanshah University of Medical Sciences, Kermanshah, Iran

    3 shared publications
  • Homayoon Bashiri

    Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran

    2 shared publications
  • Lida Haghnazari

    Department of Clinical Biochemistry, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran

    2 shared publications
  • Milad Rouhi

    Department of Food Science and Technology, School of Nutrition Sciences and Food Technology, Kermanshah University of Medical Sciences, Kermanshah, Iran

    2 shared publications
  • Susan Tahmasebi

    Department of Clinical Biochemistry, Kermanshah University of Medical Sciences, Kermanshah, Iran

    2 shared publications

Latest Publications

  • Open Access

    Upregulation of miR-32 in tissue and plasma and its association with PTEN expression in colorectal cancer

    by Bayan Mehrjoei, Susan Tahmasebi, Lida Haghnazari, Parmida Rezvani, Homayoon Bashiri, Nayebali Rezvani

    Early detection of colorectal cancer (CRC) is critical for improving patient outcomes. MicroRNAs (miRNAs) function as post-transcriptional regulators and have emerged as potential minimally invasive diagnostic biomarkers. Although miR-32 has been implicated in tumor progression in several malignancies, its expression pattern in CRC tissue and plasma and its association with PTEN expression require further clarification. Expression levels of miR-32 and PTEN were measured using quantitative real-time PCR (qRT-PCR) in tumor tissues, adjacent normal tissues, and plasma samples from 55 CRC patients and plasma samples from 55 age and sex matched healthy controls. MiR-32 expression was significantly upregulated in CRC tissues and plasma samples, whereas PTEN expression was significantly reduced in tumor tissues (P < 0.001). ROC curve analysis demonstrated strong diagnostic performance of miR-32 in tissue (AUC = 0.942) and good performance in plasma (AUC = 0.846). An inverse association between miR-32 and PTEN expression was observed. Higher miR-32 levels were also associated with advanced tumor stage. This is the first report of concurrent miR-32 upregulation and PTEN downregulation in both CRC tissue and plasma. MiR-32 may represent a potential non-invasive biomarker candidate for CRC detection and disease stratification. However, these findings are observational and require validation in larger, multicenter cohorts and functional studies before clinical application.

  • Open Access

    Evaluation of FOXF1 promoter DNA methylation as a promising epigenetic biomarker for colorectal cancer in stool samples

    by Susan Tahmasebi, Bayan Mehrjoei, Asad Vaisi-Raygani¹, Nayebali Rezvani

    Colorectal cancer pathogenesis is influenced by gene promoter region methylation, a key epigenetic mechanism. This study investigated whether FOXF1 promoter methylation in stool samples could serve as a biomarker for colorectal cancer. FOXF1 promoter methylation was analyzed in stool samples from 50 patients with colorectal cancer and 50 healthy controls. The percentage of methylation reference was determined for each sample. FOXF1 promoter methylation levels were higher in patients with colorectal cancer than in healthy controls (p < 0.001). The median percentage of methylation reference was 0.06 (95% confidence interval, 0.01–13.1) in patients and 0.01 (95% confidence interval, 0.0–0.02) in controls. Receiver operating characteristic curve analysis demonstrated a sensitivity of 59% and a specificity of 96% for FOXF1 promoter methylation in stool samples. Increased FOXF1 promoter methylation in stool samples suggests that it may serve as a noninvasive biomarker for the detection of colorectal cancer independent of sex, age, or disease stage.

  • Species identification in meat products using quantitative and qualitative PCR techniques, with emphasis on chicken detection

    by Zahra Sarlak, Nayebali Rezvani, Ehsan Parandi, Nasrin Karami, Maryam Azizi-Lalabadi, Milad Rouhi


  • Detection of caudal type homeobox 1 (CDX1) gene methylated DNA, as a stool-based diagnostic biomarker in colorectal cancer

    by Sarina Almasi, Lida Haghnazari, Seyedeh Ozra Hosseini, Nayebali Rezvani

    Colorectal cancer (CRC) is known to develop due to the accumulation of both genetic and epigenetic alterations, resulting in the conversion of intestinal epithelial cells to malignant adenocarcinoma cells. Caudal type homeobox 1 (CDX1) gene is a homeobox transcription factor and a selective tumour suppressor gene that is an important factor for the development of intestinal cells. This gene plays a role in the differentiation of intestinal epithelial cells, and its expression decreases in a number of cell lines derived from CRC, which suggests that a lack of CDX1 expression is a risk factor for the development of colorectal carcinoma. Therefore, the methylated DNA amounts of CDX1 gene in stool samples were investigated as a noninvasive method for the detection of CRC. In the present study, the methylation of CDX1 gene promoter region was assessed in stool samples of 50 CRC patients and 50 healthy individuals by MethyLight PCR using two primers and a Taq Man probe, which was completely specifically designed for fully methylated DNA of the gene promoter region. The percentage of methylated reference (PMR) of the studied gene in all samples was calculated similarly to previous studies. Statistical analysis was performed using SPSS 16. The PMR medians were 3.25 (95% CI: 0.1–100) and 0.1 (95% CI: 0.07–1) in the stool samples of CRC patients and healthy individuals, respectively. The results showed a significant difference in CDX1 gene PMR between stool samples of CRC patients and controls (P-value CDX1 gene DNA in stool samples using the MethyLight PCR has acceptable sensitivity and specificity, and is adequately potential to be used as a noninvasive complementary method for the diagnosis of CRC, along with colonoscopy as the gold standard to this end. This study is the first report on CDX1 methylation in stool samples of CRC patients. Therefore, further research should be carried out with a larger sample size to evaluate its efficacy as a diagnostic biomarker in clinical laboratories.


  • Open Access

    The influence of Nrf2 gene promoter methylation on gene expression and oxidative stress parameters in preeclampsia

    by Saba Zakeri, Zohreh Rahimi, Nayebali Rezvani, Asad Vaisi-Raygani, Reza Alibakhshi, Sahel Zakeri, Kheirolah Yari

    Background and aims: Preeclampsia (PE) is a serious medical condition that usually causes high blood pressure and affects multiple organs. Considering the adverse effect of oxidative stress on the process of PE in pregnant women and regarding the role of the Nrf2 gene in placental oxidative pathways, this study was conducted to investigate the DNA methylation status of Nrf2 in PE and healthy pregnant women. Materials and methods: The present case-control study consisted of 70 PE and 70 healthy pregnant women. Blood and placenta samples were taken from all subjects, and the percentage of the Nrf2 gene methylation in the samples was assessed by the Methyl Light PCR method. Also, the Nrf2 gene expression was evaluated by real-time PCR. The total antioxidant capacity (TAC) and total oxidative status (TOS) were measured by the colorimetric method. Results: In PE women, there was a significant increase in blood pressure, term of pregnancy, and BMI. In addition, there were enhanced Nrf2 DNA methylation percentage in placenta tissue and increased TOS levels in placenta tissue and blood compared to healthy pregnant women (P < 0.05). Also, in the PE group, there was a significant decrease in Nrf2 gene expression and TAC level in placenta tissue compared to the control group (P < 0.05). Conclusion: The Nrf2 gene undergoes epigenetic modifications of DNA hypermethylation in the PE placenta. Decreased expression of this gene and the changes in the level of oxidative parameters (TAC, TOS) confirm it.


  • Open Access

    The diagnostic potential of miR-196a-1 in colorectal cancer

    by Bayan Mehrjoei, Lida Haghnazari, Homayoon Bashiri, Nayebali Rezvani

    Background: Colorectal cancer (CRC) is a common malignancy worldwide. MicroRNAs (miRNAs) are important epigenetic alterations that notably impact various physiological and pathological processes by acting as negative regulators of gene expression. Furthermore, they have a vital function in different types of cancers, including CRC. In this research, we evaluated, for the very first time, the expression levels of miR-196a-1 in the tissue and plasma of patients with CRC and also homeobox D8 (HOXD8) as the target gene. Materials and methods: This study included a collection of 220 plasma and tissue samples from 55 patients diagnosed with CRC, as well as 55 healthy individuals matched by age and sex. Total RNA was extracted from plasma and tissue samples, and then polyadenylation and cDNA synthesis were performed. The expression levels of miR-196a-1 and HOXD8 as target gene was evaluated by quantitative RT-PCR (qRT-PCR) assay. We compared the diagnostic value of plasma miR-196a-1 with that of the circulating tumor markers CA19-9 and CEA using a Receiver Operating Characteristics (ROC) analysis. The association of miR-196a-1 with clinicopathological characteristics was assessed in tissue and plasma samples from patients with CRC. Results: Our data demonstrated that the expression levels of miR-196a-1 in the tissue and plasma samples of CRC patients were 11.426- and 11.655-fold higher, respectively than those in adjacent normal tissue and plasma samples from normal subjects (p < 0.001). Through ROC curve analysis, it was identified that the sensitivity and specificity of miR-196a-1 for tissue samples, with an AUC of 0.925, were 89% and 98%, respectively. In addition, the sensitivity and specificity for plasma samples with an AUC of 0.801 were 70% and 98%, respectively. These findings reveal that miR-196a-1 is a useful biomarker for discriminating cases from controls. Furthermore, the expression of HOXD8 was not significantly altered in tumor tissue samples compared to adjacent normal tissues (P > 0.05). Conclusions: These results show that miR-196a-1 has an oncogenic impact and plays a significant role in CRC development. The results also indicate that miR-196a-1 could serve as a novel noninvasive biomarker for the detection of CRC.


  • Open Access

    Diagnostic value of FOXF1 gene promoter-methylated DNA in the plasma samples of patients with colorectal cancer

    by Zahra Dastafkan, Nayebali Rezvani, Sabrieh Amini

    Background: Epigenetic modifications such as DNA methylation in the CpG islands of genes occur at a high rate. In this study, we measured the methylation level of the promoter region of the FOXF1 gene as a new blood biomarker for the detection of colorectal cancer in the early stages. Methods: The methylation level of the promoter region of the FOXF1 gene was measured in the plasma samples of 50 colorectal cancer patients and 50 normal individuals. DNA was extracted after exposure to sodium bisulfite by the MethyLight polymerase chain reaction (PCR) method. The percentage of promoter region was measured in all samples, and statistical analysis was done using SPSS v24 software. Results: The average promoter region between the plasma samples of colorectal cancer patients and healthy individuals had a significant difference ( P < 0.001). The average promoter region of the FOXF1 gene in tumor plasma samples was 7.1 and in the control samples was 0.48. The sensitivity and specificity of the sample plasma levels were 78% and 89.5%, respectively. Conclusion: The promoter region value of the FOXF1 gene in plasma samples using the MethyLight PCR method had high sensitivity and specificity as a non-invasive method for colorectal cancer diagnosis. This research is the first report that has been presented regarding the investigation of FOXF1 gene methylation in plasma samples in colorectal cancer. Therefore, it is necessary to conduct more studies with larger size samples to evaluate the efficiency of the gene under investigation.


  • Quantitative detection of SRY-Box 21 (SOX21) gene promoter methylation as a stool-based noninvasive biomarker for early diagnosis of colorectal cancer by MethyLight method

    by Nayebali Rezvani, Keivan Moradi, Esmaeil Babaei, MohammadAli Hosseinpour Feizi, Reza Safaralizadeh

    Ter as an appropriate candidate biomarker for differentiating CRC patients and healthy individuals for the first time. Methods: The MethyLight method was performed to analyze the methylation status of SOX21 gene promoter in fecal samples from 40 patients with CRC and 40 healthy controls. In addition, the diagnostic efficiency of measuring the hypermethylated SOX21 gene in the feces to the fecal occult blood test (FOBT) was compared. Results: The percentage of methylated reference (PMR) values in the stool of CRC patients (median 1.44) was higher than those of healthy individuals (median 0.00) (P < 0.001). A sensitivity of 72.5% and specificity of 100% were obtained for SOX21 gene promoter methylation status and 29 of the patients were considered as positive in methylation status. There was no significant association between PMR values and demographic/clinicopathological features (P > 0.05). Conclusion: The results of the present study demonstrated that the stool-based assay of SOX21 gene promoter methylation has a relatively high sensitivity and specificity and it may serve as a noninvasive biomarker for early detection of CRC. However, more studies with a wide range of samples are required to further confirm the role of hypermethylation of SOX21 in the early CRC diagnosis....